Abstract:Aim/Background: In the LL3 (345 pts recruited globally) and LL6 (364 Asian-only pts [no Japanese]) phase 3 randomized trials, first-line A, an irreversible ErbB family blocker, significantly improved OS vs cisplatin/pemetrexed (33.3 vs 21.1 months; HR 0.54; p = 0.0015) and gemcitabine/cisplatin (31.4 vs 18.4 months; HR 0.64; p = 0.023) in pts with advanced NSCLC harboring EGFR Del19 mut; no significant difference in OS was observed in EGFR L858R mut-positive patients in either study. Pre-planned subgroup analyses of OS by race including Asian, non-Asian (LL3 only), and Japanese patients (LL3 only) are reported. Methods: In each study, pts were randomized (2:1) to 40 mg/day oral A or up to 6 cycles of CT, stratified by EGFR mut (Del19/L858R/other) and race (LL3 only; Asian/non-Asian). Results: Significant improvements in OS in NSCLC pts harboring EGFR Del19 mut were observed in all race subgroups analyzed. In the Asian subgroup of LL3, median OS in Del19 pts (n = 123) was 33.3 months with A vs 22.9 months with CT (HR 0.57 [95% CI 0.36–0.90]; p = 0.015). In the non-Asian subgroup of LL3, median OS in Del19 pts (n = 46) was 33.6 months with A vs 20.0 months with CT (HR 0.45 [95% CI 0.21–0.95]; p = 0.03). In the Japanese subgroup of LL3, median OS in Del19 pts (n = 39) was 46.9 months with A vs 31.5 months with CT (HR 0.34 [95% CI 0.13–0.87]; p = 0.018). Significant improvement in OS with A vs CT was also observed in the combined analysis of Asian Del19 pts (n = 309) in LL3 and LL6 (median 31.7 vs 21.1 months; HR 0.61 [95% CI 0.46–0.82]; p = 0.001). No statistically significant difference in OS with A vs CT was observed for L858R mut pts in any of the race subgroups analyzed. Subsequent EGFR tyrosine kinase inhibitor therapy was received by 69%, 65% and 100% of non-Asian, Asian and Japanese patients, respectively, in the CT arm. Conclusions: Significant improvement in OS with first-line A vs CT in pts with NSCLC harboring EGFR Del19 mut was demonstrated in subgroup analyses of Asian, non-Asian, and Japanese pts. These findings are consistent with analysis of the overall LL3 and LL6 pooled population. Clinical trial identification: NCT00949650; NCT01121393 Disclosure: Y.-L. Wu: honoraria from Boehringer Ingelheim, Roche, AstraZeneca, Eli Lilly and Pfizer. L.V. Sequist: advisory board involvement in an uncompensated role for Boehringer Ingelheim, AstraZeneca, Clovis, Novartis, Genetech, Merrimack, and Taiho. M. Schuler: advisory board participation for AstraZeneca, Boehringer Ingelheim, Celgene, Lilly and Novartis; corporate-sponsored research for Boehringer Ingelheim and Novartis; and honoraria from Alexion, Boehringer Ingelheim, Celgene, Lilly, Novartis and Pfizer. N. Yamamoto: advisory board involvement, corporate-sponsored research and honoraria with Boehringer Ingelheim. K. O'Byrne, V. Hirsh: honoraria for advisory board involvement with Boehringer Ingelheim. T. Mok: Speaker's Bureau participant with AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, MSD, Amgen, Janssen, Clovis Oncology, GSK, and Novartis; advisory board participation for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Novartis, SFJ Pharmaceutical, and ACEA Biosciences, Inc.; honoraria from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, MSD, Amgen, Janssen, Clovis Oncology, GSK, and Novartis; and major stock shareholder in Sanomics Ltd. V. Zazulina: employment with Boehringer Ingelheim. J.C.-H. Yang: advisory board participation for Astrazeneca, Roche/Genentech, Boehringer Ingelheim, MSD, Merck Serono, Novartis, Clovis Oncology, Eli Lilly, Bayer, Celgene, Astellas, Innopharma, and Ono Pharmaceutical; and honoraria from Astrazeneca, Roche/Genentech, Boehringer Ingelheim, MSD, Merck Serono, Novartis, Clovis Oncology, Eli Lilly, Bayer, Celgene, Astellas, Innopharma, and Ono Pharmaceutical. All other authors have declared no conflicts of interest.

First-line Treatment of EGFR Mutation Adenosquamous Carcinoma of the Lung with Aumolertinib: A Multicenter, Single-Arm, Prospective Study (ARISE Study).

Efficacy and Safety of Aumolertinib Combined with or Without Chemotherapy As an Adjuvant Treatment for Stage II-IIIA Non-Small Cell Lung Cancer Following Complete Tumour Resection: the First Third-Generation EGFR-TKI Versus Chemotherapy Phase III Clinical Study (APEX).

Aumolertinib Plus Apatinib Versus Aumolertinib As First-Line Treatment in Patients with EGFR Mutation–positive Locally Advanced or Metastatic Non–small Cell Lung Cancer (NSCLC).

The Patient Outcomes with EGFR-mutated Advanced Non-Small-cell Lung Cancer Receiving Aumolertinib As First-Line Treatment.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer

Aumolertinib: A Review in Non-Small Cell Lung Cancer

Safety and Efficacy of Abivertinib (AC0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M Positive Non-Small Cell Lung Cancer (NCSLC).

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

A Modified Phase 1 Clinical Trial of Abivertinib (ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy: Topic: Phase II + NK

MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

445P Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (pts) with NSCLC Harboring EGFR Mutations (mut): Subgroup Analyses by Race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).

Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)